Hearts & Minds Blog

Resilient and Relentlessly Focused in 2017

Tim Mayleben

President and Chief Executive Officer

Happy New Year! We welcomed 2017 with tremendous momentum as we advanced our bempedoic acid (ETC-1002) pivotal Phase 3 LDL cholesterol lowering development program – including steadily reducing the overall program risk. The Esperion team is relentless and resilient, and we remain focused on patients and their physicians waiting on new, non-statin, complementary, cost-effective, convenient, oral, once-daily LDL-C lowering therapies. They provide us the motivation to do what we do best. First, I want to start with an update on one such patient: my wife,… more

Bempedoic Acid Mechanism of Action Paper Published in Nature Communications: Q&A with the Authors

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

Narendra Lalwani, PhD, MBA, FAHA

Executive Vice President, Research and Development, and Chief Operating Officer

Steve Pinkosky

Senior Scientist, Head of Translational Research

As you may have seen, Esperion scientists and collaborators recently published the definitive paper on the mechanism of action for bempedoic acid, “Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis,” in the journal Nature Communications. I sat down with authors and colleagues Narendra Lalwani and Steve Pinkosky to discuss our findings, highlights from our research and ultimately why this publication reinforces that “mechanism matters”. Marianne Andreach: Briefly describe the findings and the importance of bempedoic acid’s mechanism of action over the course… more

The History of LDL-Cholesterol with Dr. Antonio Gotto

Antonio M. Gotto, Jr., MD, DPhil

Dean Emeritus and Co-Chair of Board of Overseers, Weill Cornell Medical College

Tim Mayleben

President and Chief Executive Officer

As you know, Esperion is focused on developing and commercializing therapies for the treatment of patients with hypercholesterolemia who are not adequately controlled by currently available lipid-modifying therapies. Like any medical innovation, the journey of bempedoic acid started long before Esperion with the earliest identification of LDL-cholesterol (LDL-C) more than a century ago. So as National Cholesterol Education Month recently came to a close, we thought this would be an appropriate time to break down the history of LDL-C lowering. Today, research and understanding of… more

Highlights from the 2016 ESC Congress

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

Tim Mayleben

President and Chief Executive Officer

Buongiorno from the ESC Congress! Earlier this week we had the opportunity to attend the 2016 European Society of Cardiology (ESC) Congress in Rome. ESC has become the largest cardiology meeting in the world with more than 32,000 physicians and other healthcare care professionals in attendance this year. This is one of the most important scientific events of the year for cardiovascular disease research, particularly for those focused on developing drugs to help patients around the world lower their levels of LDL-cholesterol. Key highlights we… more

Olympic Reflection: Team USA and Team Esperion

Tim Mayleben

President and Chief Executive Officer

Perhaps, like me, you’ve been watching the Rio 2016 Summer Olympic Games, reading about the Olympics online and in print, and talking about the Olympics with friends and co-workers.  The Olympics have been exciting to watch – and exhausting to keep up with!  Dawn now considers herself an “Olympics widow”. There are always inspiring Olympic storylines but one relatively under-reported story in particular caught my attention. While women represent 51 percent of the US population, did you know that for the second straight Summer Olympics,… more